{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:06:54Z","timestamp":1781086014631,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/bf03261924","type":"journal-article","created":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T20:16:56Z","timestamp":1357244216000},"page":"707-714","source":"Crossref","is-referenced-by-count":28,"title":["Cognitive Effects of Oxybutynin Chloride Topical Gel in Older Healthy Subjects"],"prefix":"10.1007","volume":"32","author":[{"given":"Gary G.","family":"Kay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Staskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"MacDiarmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"McIlwain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi V.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"issue":"10","key":"1924_CR1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2165\/00003495-200666100-00005","volume":"66","author":"R.A. Appell","year":"2006","unstructured":"Appell RA. Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent. Drugs 2006; 66(10): 1361\u201370","journal-title":"Drugs"},{"key":"1924_CR2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4065\/78.6.696","volume":"78","author":"R.A. Appell","year":"2003","unstructured":"Appell RA, Chancellor MB, Zobrist RH, et al. Pharmaco-kinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003; 78: 696\u2013702","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"1924_CR3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0022-5347(01)65148-6","volume":"157","author":"K. Waldeck","year":"1997","unstructured":"Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997 Mar; 157(3): 1093\u20137","journal-title":"J Urol"},{"issue":"18","key":"1924_CR4","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1517\/14656560903451682","volume":"10","author":"D.R. Staskin","year":"2009","unstructured":"Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother 2009; 10(18): 3103\u201311","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"1924_CR5","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1742-1241.2008.01849.x","volume":"62","author":"G.G. Kay","year":"2008","unstructured":"Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008; 62(11): 1792\u2013800","journal-title":"Int J Clin Pract"},{"key":"1924_CR6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","volume":"50","author":"G. Kay","year":"2006","unstructured":"Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50: 317\u201326","journal-title":"Eur Urol"},{"issue":"Suppl. 5A","key":"1924_CR7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0090-4295(99)00492-6","volume":"55","author":"C.R. Chapple","year":"2000","unstructured":"Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55 Suppl. 5A: 33\u201346","journal-title":"Urology"},{"key":"1924_CR8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","volume":"100","author":"P. Abrams","year":"2007","unstructured":"Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987\u20131006","journal-title":"BJU Int"},{"key":"1924_CR9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(05)66095-8","volume":"166","author":"G.W. Davila","year":"2001","unstructured":"Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166: 140\u20135","journal-title":"J Urol"},{"key":"1924_CR10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00345-005-0012-8","volume":"23","author":"R.R. Dmochowski","year":"2005","unstructured":"Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005; 23: 263\u201370","journal-title":"World J Urol"},{"key":"1924_CR11","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.juro.2008.11.125","volume":"181","author":"D.R. Staskin","year":"2009","unstructured":"Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 2009 Apr; 181: 1764\u201372","journal-title":"J Urol"},{"issue":"2","key":"1924_CR12","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0022-5347(05)64684-8","volume":"168","author":"R.R. Dmochowski","year":"2002","unstructured":"Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002 Aug; 168(2): 580\u20136","journal-title":"J Urol"},{"key":"1924_CR13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1464-410X.2006.06658.x","volume":"99","author":"P. Sand","year":"2007","unstructured":"Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007; 99: 836\u201344","journal-title":"BJU Int"},{"issue":"7","key":"1924_CR14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/00498259209053145","volume":"22","author":"K.M. Hughes","year":"1992","unstructured":"Hughes KM, Lang JC, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992; 22(7): 859\u201369","journal-title":"Xenobiotica"},{"key":"1924_CR15","unstructured":"GELNIQUE (oxybutynin chloride) 10% gel [package insert]. Corona (CA): Watson Pharmaceuticals, Inc., Jan 2009"},{"key":"1924_CR16","volume-title":"Neuropsychologicial assessment of neuropsychiatric and neuromedical disorders","author":"T. Crook","year":"2009","unstructured":"Crook T, Kay G, Larrabee G, et al. Computer based cognitive testing. In: Igor Grant, Kenneth Adams, editors. Neuropsychologicial assessment of neuropsychiatric and neuromedical disorders, 3rd ed. New York (NY): Oxford University Press, 2009","edition":"3"},{"issue":"1","key":"1924_CR17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1037\/0022-006X.59.1.12","volume":"59","author":"N.S. Jacobson","year":"1991","unstructured":"Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy-research. J Consult Clin Psychol 1991; 59(1): 12\u20139","journal-title":"J Consult Clin Psychol"},{"issue":"6","key":"1924_CR18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1017\/S1355617700001739","volume":"2","author":"S.M. Sawrie","year":"1996","unstructured":"Sawrie SM, Chelune GJ, Luders HO. Empirical methods for assessing meaningful neuropsychological change following epilepsy surgery. J Int Neuropsychol Soc 1996; 2(6): 556\u201364","journal-title":"J Int Neuropsychol Soc"},{"key":"1924_CR19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1464-410X.2005.05296.x","volume":"95","author":"K. Diefenbach","year":"2005","unstructured":"Diefenbach K, Arold G, Wollny A, et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged \u226550 years. BJU Int 2005; 95: 346\u20139","journal-title":"BJU Int"},{"key":"1924_CR20","unstructured":"Kay G, Kardiasmenos K, Crook T. Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects [abstract no. 87]. Annual Meeting of the International Continence Society; 2006 Nov 27\u2013Dec 1; Christchurch, New Zealand [online]. Available from URL: https:\/\/www.icsoffice.org\/Abstracts\/Publish\/44\/000087.pdf [Accessed 2012 Jan 11]"},{"issue":"7","key":"1924_CR21","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1010956832113","volume":"18","author":"R.H. Zobrist","year":"2001","unstructured":"Zobrist RH, Schmid B, Feick A, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-dese-thyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001; 18(7): 1029\u201334","journal-title":"Pharm Res"},{"issue":"8","key":"1924_CR22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2165\/11588990-000000000-00000","volume":"31","author":"R.R. Dmochowski","year":"2011","unstructured":"Dmochowski RR, Newman DK, Sand PK, et al. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, showering, sunscreen, and person-to-person transference. Clin Drug Investig 2011; 31(8): 559\u201371","journal-title":"Clin Drug Investig"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261924.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03261924\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T01:41:48Z","timestamp":1558489308000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03261924"}},"subtitle":["A 1-Week, Randomized, Double-Blind, Placebo- and Active-Controlled Study"],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["1924"],"URL":"https:\/\/doi.org\/10.1007\/bf03261924","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}